Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn
Primary Purpose
Heart Diseases
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Digoxin
Hawthorn
Sponsored by

About this trial
This is an interventional treatment trial for Heart Diseases focused on measuring Digoxin, Effect modifiers (Epidemiology), Rosales, Drug Interaction
Eligibility Criteria
Inclusion Criteria: Healthy adult Not regularly taking any prescription or non-prescription medications (including natural products or supplements) and is willing to avoid all medications other than the study drugs during the study period. Willing to avoid drinking any alcohol throughout the study period. Does not currently smoke and is willing to avoid smoking during the study period. Willing to adhere to dietary restrictions as required during the study.
Sites / Locations
- Univ. of Michigan Medical Center
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00006330
First Posted
October 4, 2000
Last Updated
June 23, 2005
Sponsor
National Center for Research Resources (NCRR)
1. Study Identification
Unique Protocol Identification Number
NCT00006330
Brief Title
Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn
Study Type
Interventional
2. Study Status
Record Verification Date
November 2001
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Center for Research Resources (NCRR)
4. Oversight
5. Study Description
Brief Summary
Hawthorn (Crataegus oxyacantha) is a natural product that is popular in European and American herbal medicine practice. Some of its cardiac uses include the treatment of high and low blood pressure, rapid heart beat, chest pain, and blocked arteries. In many cases, it is used as an adjuvant agent with other cardiac drugs such as digoxin, amiodarone, and warfarin. To date, little information is known about the effect of hawthorn when taken with other drugs and if toxicities occur when hawthorn is used with other drugs. The purpose of this study is to examine the interaction between digoxin and hawthorn in eight healthy subjects. Subjects will be recruited by advertisement. The design of the study will include a 10-day and a three-week treatment phase of digoxin 0.125 mg - 0.25 mg/day and hawthorn (Crataegus special extract WS1442, Schwabe Co.) 450 mg twice daily or placebo, with a randomized crossover. There will be a three-week washout period in between treatment phases. On day 10 (phase I) and day 21 (phase II), subjects will have 12 blood samples drawn for pharmacokinetic analysis. The plasma samples will be measured for digoxin concentration. Additionally, the subjects will be assessed for any clinical toxicities or adverse events. The significance of this study is to provide the clinician with information regarding the safe use of digoxin in combination with the herbal supplement, hawthorn.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Diseases
Keywords
Digoxin, Effect modifiers (Epidemiology), Rosales, Drug Interaction
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Digoxin
Intervention Type
Drug
Intervention Name(s)
Hawthorn
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy adult
Not regularly taking any prescription or non-prescription medications (including natural products or supplements) and is willing to avoid all medications other than the study drugs during the study period.
Willing to avoid drinking any alcohol throughout the study period.
Does not currently smoke and is willing to avoid smoking during the study period.
Willing to adhere to dietary restrictions as required during the study.
Facility Information:
Facility Name
Univ. of Michigan Medical Center
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109-0008
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn
We'll reach out to this number within 24 hrs